Lodenafil Carbonate

• CAT Number: R058346
• CAS Number: 398507-55-6
• Molecular Formula: C47H62N12O11S2
• Molecular Weight: 1035.206
• Purity: 95%
• Storage: Store at -20°C
• IUPAC Name: bis[2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]ethyl] carbonate
• InChI: InChI=1S/C47H62N12O11S2/c1-7-11-35-39-41(54(5)52-35)45(60)50-43(48-39)33-29-31(13-15-37(33)67-9-3)71(63,64)58-21-17-56(18-22-58)25-27-69-47(62)70-28-26-57-19-23-59(24-20-57)72(65,66)32-14-16-38(68-10-4)34(30-32)44-49-40-36(12-8-2)53-55(6)42(40)46(61)51-44/h13-16,29-30H,7-12,17-28H2,1-6H3,(H,48,50,60)(H,49,51,61)
• InChIKey: MVYUCRDXZXLFSB-UHFFFAOYSA-N
• SMILES: CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CCOC(=O)OCCN5CCN(CC5)S(=O)(=O)C6=CC(=C(C=C6)OCC)C7=NC(=O)C8=C(N7)C(=NN8C)CCC)OCC)C

Lodenafil carbonate(cas 398507-55-6) is a new PDE-5 inhibitor used for oral therapy in erectile dysfunction

Reference

1: Codevilla CF, Castilhos Tdos S, Cirne CA, Froehlich PE, Bergold AM.
Development and validation of a dissolution test for lodenafil carbonate based on
in vivo data. Drug Dev Ind Pharm. 2014 Apr;40(4):488-93. doi:
10.3109/03639045.2013.768633. Epub 2013 Apr 24. PubMed PMID: 23614829.

2: Nunes LV, Lacaz FS, Bressan RA, Nunes SO, Mari Jde J. Adjunctive treatment
with lodenafil carbonate for erectile dysfunction in outpatients with
schizophrenia and spectrum: a randomized, double-blind, crossover,
placebo-controlled trial. J Sex Med. 2013 Apr;10(4):1136-45. doi:
10.1111/jsm.12040. Epub 2013 Jan 25. PubMed PMID: 23350632.

3: Mendes GD, dos Santos Filho HO, dos Santos Pereira A, Mendes FD, Ilha JO,
Alkharfy KM, De Nucci G. A Phase I clinical trial of lodenafil carbonate, a new
phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers. Int J Clin
Pharmacol Ther. 2012 Dec;50(12):896-906. doi: 10.5414/CP201624. PubMed PMID:
23073140.

4: Codevilla CF, Lemos AM, Delgado LS, Rolim CM, Adams AI, Bergold AM.
Development and validation of a stability-indicating LC method for the assay of
lodenafil carbonate in tablets. J Chromatogr Sci. 2011 Aug;49(7):502-7. PubMed
PMID: 21801480.

5: Silva AC, Toffoletto O, Lucio LA, Santos PF, Afiune JB, Massud Filho J, Tufik
S. [Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor,
with and without alcohol consumption]. Arq Bras Cardiol. 2010 Feb;94(2):150-6,
160-7, 152-8. English, Portuguese, Spanish. PubMed PMID: 20428608.

6: Glina S, Fonseca GN, Bertero EB, Damião R, Rocha LC, Jardim CR, Cairoli CE,
Teloken C, Torres LO, Faria GE, da Silva MB, Pagani E. Efficacy and tolerability
of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III
clinical trial. J Sex Med. 2010 May;7(5):1928-36. doi:
10.1111/j.1743-6109.2010.01711.x. Epub 2010 Feb 25. PubMed PMID: 20214718.

7: Glina S, Toscano I, Gomatzky C, de Góes PM, Júnior AN, Claro JF, Pagani E.
Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile
dysfunction: a phase II clinical trial. J Sex Med. 2009 Feb;6(2):553-7. doi:
10.1111/j.1743-6109.2008.01079.x. Epub 2008 Nov 17. PubMed PMID: 19040623.

8: Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G.
Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5)
inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J
Pharmacol. 2008 Sep 4;591(1-3):189-95. doi: 10.1016/j.ejphar.2008.06.055. Epub
2008 Jun 19. PubMed PMID: 18593576.